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1. Introduction
Fertility preservation is an emerging discipline that now has a key place in the care of re‐
productive-aged women with cancer. Because of improvement in diagnostic and therapeu‐
tic strategies,  an increasingly larger number of women are surviving with cancer. In the
US, more than 11 million are living with cancer and approximately 450,000 cancer survi‐
vors are of reproductive age. In addition, 4-5% of new cancer patients are younger than 35
years [1]. As a result, quality-of-life issues, including those involving fertility preservation,
have gained a significant importance in the care of women with cancer.
Ovarian tissue cryopreservation and reimplantation is a main option to preserve their fer‐
tility in cancer patients who need cancer treatments without delay or do not want to un‐
dergo ovarian stimulation. For prepubertal girls with cancer, ovarian tissue freezing is the
only option for fertility preservation. The first case of human ovarian tissue cryopreserva‐
tion and auto-transplantation was reported in the year 2000 [2]. To date, a total of 17 ba‐
bies from 12 patients have been born worldwide from ovarian tissue cryopreservation and
reimplantation [3].
Even with remarkable advances in technology and increasing enthusiasm for clinical ap‐
plications,  human ovarian  tissue  transplantation  is  still  considered as  an  investigational
method.  There  are  many uncertainties  and unanswered questions  including the  restora‐
tion of ovarian function after transplantation. Thus, in this chapter, we would like to re‐
view  the  concepts  and  methods  of  fertility  preservation,  and  endocrine  function  after
ovarian transplantation in terms of sex steroid production from the cryopreserved and re‐
implanted ovary.
© 2012 Lee and Ku; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Gonadal damage
Chemotherapy and radiotherapy can cause severe gonadal damages resulting in amenor‐
rhea with ovarian follicle loss in female and azoospermia in male. Adjuvant chemotherapy
particularly with alkylating agents such as cyclophosphamide is gonadotoxic and induces
premature ovarian failure. The drugs are generally classified as high risk (e.g. cyclophos‐
phamide, chlorambucil, melphalan, busulfan, nitrogen mustard, and procarbazine), inter‐
mediate risk (e.g. cisplatin, and adriamycin), and low risk (e.g. methotrexate, 5-fluorouracil,
vincristine, bleomycin, and actinomycin D) [4]. (Table 1) The degree of chemotherapy-in‐
duced ovarian damage is dependent on the patient’s age, the drug used, and the dosage of
the drugs. Since most cancer patients are treated with multi-agent chemotherapy protocols,
it is not easy to assess the degree of gonadal damage caused by a single specific agent. Radi‐
otherapy-induced follicular damage resulting in a high risk of prolonged amenorrhea in
women can occur when exposed by pelvic or whole abdominal radiation dose ≥6 Gy in
adult women, ≥10 Gy in postpubertal girls, and ≥15 Gy in prepubertal girls [5-9]. The radia‐
tion dose of concurrent chemoradiation therapy (CCRT) for patients with advanced stage
cervical cancer is usually about 50 Gy. Thus gynecologic oncologists should consider a pos‐
sibility of post-treatment infertility in patients who undergo CCRT.
High risk Intermediate risk Low risk
Cyclophosphamide Cisplatin Methotrexate
Chlorambucil Adriamycin 5-Fluorouracil
Melphalan Vincristine
Busulfan Bleomycin
Nitrogen mustard Actinomycin D
Procarbazine
Table 1. The degree of gonadal damage by chemotherapy [4]
3. Candidates for and determinants of access to fertility preservation
Candidates for fertility preservation include patients with childhood cancers, breast cancers,
gynecologic cancers, hematologic cancers such as leukemia and lymphoma, those who need
hematopoietic stem cell transplantation or pelvic irradiation for other diseases, and those
with a high risk of premature ovarian failure (or primary ovarian insufficiency). Since nu‐
merous departments are involved in fertility preservation treatment, collaborating as a team
with several specialists who take part in the initial cancer diagnosis and treatment, includ‐
ing a mental health provider, is necessary to manage cancer patients.
Although under ideal circumstances patients should be referred to fertility preservation spe‐
cialists before chemotherapy; however, many of those who do not have this opportunity
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may develop infertility and may be referred for post-chemotherapy assisted reproduction
[10]. Because the likelihood of the success of assisted reproductive techniques after chemo‐
therapy is significantly diminished [11], it is extremely important to understand the factors
that determine the access to fertility preservation and early referral. In a previous study, we
evaluated the socioeconomic, demographic, and medical factors that influence early referral
(before cancer treatment) to fertility preservation versus delayed referral to post-chemother‐
apy assisted reproduction in 314 women with breast cancer. Factors favoring referrals for
fertility preservation were older age, early stage breast cancer, cancer care at an academic
center, and family history of breast cancer [12]. This information has revealed the barriers
against accessing early fertility preservation care.
4. Importance of early referral to fertility preservation
Oncologists should recognize the importance of fertility preservation and early referral to
specialists. Both embryo and oocyte freezing for fertility preservation require ovarian stimu‐
lation with gonadotropins. Since ovarian stimulation must be started within the first four
days of the menstrual cycle to be effective, and requires approximately two weeks for com‐
pletion, early referral is crucial to avoid delay in chemotherapy. The author’s previous study
concluded that early referral prior to breast surgery enables women with breast cancer to
initiate a fertility preservation cycle sooner and to undergo multiple cycles of oocyte or em‐
bryo freezing, when desired. Referral prior to breast surgery (n=35) results in the initiation
of chemotherapy on average 3 weeks earlier in single fertility preservation cycles, as well as
when the data from double cycles are included, compared to those referred after breast sur‐
gery (n=58). This additional time allows patients to undergo multiple cycles of fertility pres‐
ervation (9/35 vs. 1/58). Women who can undergo multiple cycles are likely to be at an
advantage for fertility preservation because of the additional number of eggs or embryos
generated [13].
A recent study, however, indicated that still less than half of physicians routinely refer can‐
cer patients of childbearing age to reproductive specialists [14]. Another recent study report‐
ed that while most oncologists recognize the importance of discussing infertility risks after
cancer treatment, few actually discuss fertility preservation with their patients [15]. In addi‐
tion, Armuand et al. [16] reported that there have been sex differences in access to fertility-
related information and the use of fertility preservation treatment. Only half of the women
had discussed fertility issues with a health care professional, although the majority of men
had received information about fertility preservation such as sperm cryopreservation [16].
Potential explanations are that sperm banking for men is an easy and well established meth‐
od, and that the delay is negligible compared to the required duration of ovarian stimula‐
tion for embryo or oocyte cryopreservation.
Oncologists play a key role in understanding patients’ concerns regarding fertility. Fertility
preservation specialists should make an effort to publicize the significance of fertility preser‐
vation for reproductive women with cancer and should provide appropriate education for
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both associated physicians and cancer patients who wish to preserve their fertility. As im‐
portant as it is to encourage oncologists to refer young people with cancer to fertility preser‐
vation counseling, it is just as important to emphasize referral as early in the process as
possible to maximize the likelihood of success.
5. Standard methods for fertility preservation
The American Society of Clinical Oncology (ASCO) has issued practice guidelines for fertili‐
ty preservation options in cancer patients [17]. Several well established methods of fertility
preservation have been introduced, including embryo cryopreservation, gonadal shielding
during radiotherapy, trachelectomy, and ovarian transposition. (Table 2)
Standard methods Experimental methods
Embryo cryopreservation Oocyte cryopreservation
Gonadal shielding during radiation therapy Ovarian cryopreservation and transplantation
Ovarian transposition (oophoropexy) Ovarian suppression with GnRH analogs or antagonists
Trachelectomy
Other conservative gynecologic surgery
Table 2. Fertility preservation options in females [17]
Embryo cryopreservation is a well-established technique and the current live-birth rate per
transfer using frozen thawed embryos is 35.6% in US women under 35-year-old (http://
www.sart.org, 2008). Embryo freezing should initially be considered for fertility preserva‐
tion treatment if there is adequate time for ovarian stimulation and a partner or donor
sperm.
Gonadal shielding during radiotherapy should be considered if radiotherapy is required for
cancer treatment. For example, radiation plays an important role in the management of
breast cancer, which can be classified into four categories: 1) Primary radiotherapy in breast-
conserving treatment for early breast cancer, 2) Adjuvant radiotherapy after mastectomy for
high-risk patients, 3) Radiotherapy after neo-adjuvant chemotherapy in locally-advanced
breast cancers, and 4) Palliative radiotherapy for metastatic disease [18].
Trachelectomy is also an accepted method for the surgical management of early stage cervi‐
cal cancer in women who wish to preserve their fertility. Cervical cancer is one of the most
common cancers in women younger than 40 along with breast cancer, non-Hodgkin’s lym‐
phoma, and leukemia [19]. Indications for trachelectomy are described in Table 3.
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1. Women who desire to preserve fertility (age<40-45)
2. Stage Ia1a (with lymph vascular space involvement), Ia2, Ib1
3. Lesion size ≤2 cm
4. Histologically squamous, adeno-, or adenosquamous carcinoma
5. No upper cervical canal involvement of cancer
6. No evidence of lymph node metastasis
aConization, Ia1 without lymph vascular space involvement
Table 3. Indications for trachelectomy in cervical cancer [20]
Plante et al. [20] reported their experience with 125 patients who underwent vaginal radical
trachelectomy. The recurrence rate of cervical cancer after trachelectomy was less than 5%
and the death rate was less than 2%. Having lesions sized >2 cm was a strong risk factor for
recurrence. A total of 58 women out of 125 conceived a total of 106 pregnancies, and of
those, 73% of pregnancies reached the third trimester, of which, in turn, 75% gave birth at
term. Overall, 13.5% of patients were associated with fertility problems.
Ovarian transposition can be performed not only for preservation of fertility but also for
prevention of premature ovarian failure in cervical cancer patients who require radiothera‐
py. It is necessary for gynecologic oncologists to understand the field of radiotherapy to pre‐
pare for ovarian transposition. Usually, standard fields are used with the upper field border
on the fourth/fifth lumbar vertebra [21]. It is widely accepted that surgical transposition
should be at least 3 cm above the upper border of the radiation field [22]. Hwang et al. [23]
reported that a location for the transposed ovary higher than 1.5 cm above the iliac crest is
recommended to avoid ovarian failure after primary or adjuvant pelvic radiotherapy in cer‐
vical cancer.
To date, the remaining methods are considered to be experimental, although the oocyte sur‐
vival rate (81% vs. 68%) and live-birth rate per embryo transfer (34% vs. 14%) of oocyte cryo‐
preservation with vitrification is significantly higher than with conventional slow freezing
methods [24]. Noyes et al. [25] asked whether it is “time to remove the experimental label” of
oocyte cryopreservation. Because of the improvements in advanced technologies including
freezing-thawing methods, a new guideline is necessary to update fertility preservation spe‐
cialists with the latest knowledge.
6. Ovarian cryopreservation and transplantation
The first ovarian transplant with cryopreserved ovarian tissue was performed by Dr. Kutluk
Oktay in 1999 [25]. In 2004, Dr. Donnez reported the first successful birth from slow, or con‐
trolled rate, frozen ovarian tissue [26].In 1997, samples of ovarian cortex were taken from a
woman with Hodgkin’s lymphoma and cryo-preserved in a rate freezer and stored in liquid
nitrogen. After chemotherapy the patient had premature ovarian failure. In 2003, after
freeze-thawing, orthotopic autotransplantation of ovarian cortical tissue was done by lapa‐
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roscopy and five months after reimplantation signs indicated recovery of regular ovulatory
cycles. A viable intrauterine pregnancy was confirmed eleven months after reimplantation
that resulted in a live birth.
The first case report of nonautologous orthotopic transplantation of fresh ovarian tissue was
from one monozygotic twin sister to the other, who had suffered from premature ovarian
failure [27]. The procedure resulted in a live birth. These investigators have repeated this
procedure in 10 sets of monozygotic twins [28], and successfully transplanted an intact fresh
ovary [29]. Others have reported a live birth after allografting of ovarian cortex between
monozygotic twins with Turner mosaic and discordant ovarian function [30].
Human ovarian tissues have been xenotransplanted to immunodeficient mice, with subse‐
quent ovulation [31-33]; however, aberrant microtubule organization and chromatin pat‐
terns observed during the maturation process are of significant concern [34,35]. The risk of
contamination with trans-species retroviral infections also needs to be addressed prior to
testing this experimental approach clinically.
Successful pregnancies after ovarian tissue cryopreservation followed by transplantation
have been reported in some human studies [36-39]. Transplantation of cryopreserved ovari‐
an tissue has shown to be a potential method for recovery of ovarian function [2]. Advantag‐
es of ovarian tissue transplantation are not only preservation of fertility but also restoration
of endocrine function in young women after cancer treatment.
Ovarian tissue cryopreservation and reimplantation is a main option for preserving the fer‐
tility of cancer patients who need cancer treatments without delay or do not want to under‐
go ovarian stimulation. For prepubertal girls diagnosed with cancer, ovarian tissue freezing
is the only option for fertility preservation. To date, a total of 17 babies from 12 patients have
been born worldwide from ovarian tissue cryopreservation and reimplantation [3]. Based on
the site of reimplantation of cryopreserved ovarian tissue, transplantation can be classified
into two different types: orthotopic (e.g. to remaining ovarian tissue or pelvic peritoneum)
and heterotopic(e.g. in the abdominal wall, forearm, and chest wall) transplantation.
7. Sex steroid production from cryopreserved and reimplanted ovary
7.1. Types of sex steroids
Sex steroids or gonadal steroids are steroid hormones that interact with androgen or estro‐
gen receptors [40]. Their effects are mediated by slow genomic mechanisms through nuclear
receptors as well as by fast nongenomic mechanisms through membrane-associated recep‐
tors and signaling cascades [41]. The non-steroid hormones such as luteinizing hormone
(LH), follicle-stimulating hormone (FSH) and gonadotropin-releasing hormone (GnRH) are
usually not considered as sex hormones, even though they mainly play sex-related roles.
Natural sex steroids are produced by the gonads, adrenal glands, or conversion from other
sex steroids in other tissues such as the liver or fat [42].
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Two main classes of sex steroids are androgens and estrogens and their human derivatives
are testosterone and estradiol, respectively. Progestogen is also regarded as a third class of
sex steroids. Progesterone is the most important and only naturally-occurring human pro‐
gestogen. In general, androgens are considered "male sex hormones", while estrogens and
progestagens are considered as "female sex hormones".
Androgens Estrogens Progestogens
Anabolic steroids Estradiol Progesterone
Androstenedione Estriol
Dehydroepiandrosterone Estrone
Dihydrotestosterone
Testosterone
Table 4. Types of sex steroids [40,41]
Transplantation of cryopreserved ovarian tissue has shown to be a potential method for re‐
covery of ovarian function [2]. Advantages of ovarian tissue transplantation are not only
preserving fertility but also restoring endocrine function in young women after cancer treat‐
ment. In a review of successful orthotopic frozen-thawed ovarian reimplantation, restora‐
tion of ovarian activity was shown to be between 3.5 and 6.5 months after transplantation
[43]. Oktay et al. [2,44] reported the first case of laparoscopic transplantation of frozen-
thawed ovarian tissue into the pelvic sidewall with subsequent ovulation and subcutaneous
ovarian transplantation to the forearm, which resulted in preserved endocrine function and
follicular development. Approximately 10 weeks after ovarian transplantation to the fore‐
arm, endocrine function was restored with decreased FSH and LH levels, and cyclical varia‐
tion of peripheral estradiol levels [44]. Silber reported the recovery of ovarian function in
terms of recovery of menstrual cycles and hormone levels (FSH) approximately 80 to 140
days after reimplantation from their fresh and frozen transplant cases [3].
7.2. The longevity of ovarian transplantation
Dr. Kim reported the longevity of ovarian grafts in five cancer patients who underwent het‐
erotopic autotransplantation of frozen-thawed ovarian tissue between 2001 and 2011 [45].
The age of patients at the time of ovarian transplantation was between 30 and 40. Cryopre‐
served ovarian tissue (for 1–10 years) was rapidly thawed and transplanted into the space
between the rectus sheath and muscle. Endocrine function was measured by monthly blood
tests (FSH, LH, E2, progesterone and testosterone) and ultrasound after transplantation. The
monitoring was continued until the cessation of endocrine function had been confirmed by
consecutive blood tests (E2<20 pg/mL; FSH≥35 IU/L).
Endocrine function was restored in all patients between 12–20 weeks after ovarian tissue
transplantation. Four patients required the second transplantation one to two years after the
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first transplantation. The duration of endocrine function after the second transplantation
was much longer (9–84 months). The longest duration of endocrine function was observed
in a patient who underwent ovarian transplantation in 2003 and 2004 after radiotherapy for
cervical cancer. Even for more than seven years after transplantation, endocrine function
had not ceased (FSH 9.5 IU/L, E2 108 pg/mL). She underwent three IVF cycles which resulted
in four embryos.
The longevity of grafted ovarian tissue has been debated for many years. The duration of
endocrine function after frozen-thawed ovarian tissue transplantation is still uncertain. Dr.
Kim described that the endocrine function lasting for seven years can be established with
heterotopic transplantation of cryobanked human ovarian tissue. This information will ben‐
efit young cancer survivors with premature ovarian failure.
In the UK, researchers indicated that the duration of graft life is greater than 7 years [46].Un‐
doubtedly, the length of time the grafts function will depend on several factors [45, 46].
1. Age at the time of cryopreservation
2. Baseline ovarian reserve
3. History of cancer treatment
4. Techniques of ovarian tissue preparation
5. Freezing-thawing protocols
6. Number of cortical tissue grafted
7. Techniques and sites of transplantation
8. Degree of ischemia after transplantation
9. Number of follicles in the ovarian grafts
Table 5. Factors associated with the longevity of grafted ovarian tissue [45,46]
One of the most important factors may be the number of eggs’ survival during the freezing-
thawing and revascularization process. If one makes an assumption that one third of an ova‐
ry is transplanted into the patient (the proportion quoted in the linked report), and that
during revascularization two thirds of the immature eggs are lost,[47,48] then we can calcu‐
late how many immature eggs are likely to survive the freeze/thaw and revascularization
process to ensure that >1000 non-growing follicles are successfully transplanted (the number
present at the menopause) [49,50]. It has been estimated that at age 36.9 years insufficient
non-growing follicles will remain after cryopreservation to sustain ovarian function in 40%
of the healthy population. At age 40 years we estimate that 60% of healthy women will be
unlikely to benefit from ovarian cryopreservation.
We need to assess the indications and risk-benefit analysis carefully for future patients. The
value of ovarian cryopreservation to preserve fertility for young cancer survivors may be
proven, however the indications for those who should be offered this new technology are
not yet established.
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7.3. Ovarian function after isotransplantation
Dr. Silber reported his novel experience about the nine identical twin pairs discordant for
premature ovarian failure that underwent their orthotopic ovarian isotransplantation be‐
tween 2004 and 2008 [27]. All of these fresh ovary transplants were successful, resulting in
11 healthy babies in 7 of the 9 recipients. The same surgical techniques were then applied to
3 frozen ovary tissue transplants, up to 14 years after the ovary had been frozen, resulting in
3 more healthy babies [28,29].
Silber et al reported that the first rise in estradiol was observed 71 days after implantation of
fresh tissue [27]. In their published series, the time to first menses after transplantation
ranged between 65 to 93 days [28]. Recipients routinely resumed ovulatory menstrual cycles
and normal Day 3 serum FSH levels by 4.5 months. Most conceived naturally (three of them
twice or three times from the same graft). The duration of function of fresh ovarian grafts
indicated minimal oocyte loss from ischemia period. Grafts of just modest portions of ovari‐
an tissue have lasted >7 years. In vitro studies suggest that vitrification of ovarian tissue may
be an improvement over the 70% oocyte viability loss from slow freeze [29].
This newly favorable experience is not limited just to one center [43]. Equally robust results
are being experienced in Brussels, Paris, Spain, Denmark and Israel. Frozen ovarian grafts
with the slow freeze technique in Denmark are lasting over 5 years and many spontaneous
pregnancies have been reported without IVF techniques or other adjuvant treatment. To
date, 28 healthy babies have been born from ovarian tissue grafting including fresh/frozen
ovarian tissue transplantation, and most involved no IVF, and resulted from just regular in‐
tercourse without any other treatment [2].
7.4. Ovarian function after allogenic transplantation
Recently, autologous orthotopic transplantation of cryopreserved ovarian tissue has resulted
in live births. Dr. Donnez reported three cases of ovarian transplantation between two ge‐
netically non-identical sisters in 2010 [51]. The three recipient patients presented with iatro‐
genic premature ovarian failure due to chemotherapy and radiotherapy. The recipients had
all received bone marrow and ovarian tissue from their HLA-compatible sisters in each case.
None of the recipients were on any steroid or immunosuppressive therapy and all presented
with documented premature ovarian failure. Their ovaries were atrophic and serial sections
of biopsies failed to demonstrate the presence of any follicles. Premature ovarian failure was
confirmed by very high FSH and LH levels, very low estradiol concentrations and the ab‐
sence of follicles in large biopsies removed from the patients’ atrophic ovaries during trans‐
plantation. For the first time, successful restoration of ovarian function after transplantation
of ovarian cortex between genetically different sisters was reported.
The time interval between implantation of ovarian tissue and follicular development was
found to be between 3.5 and 6 months, consistent with the previous study by Silber et al [27].
The time interval of 6 months observed in patients 1 was associated with a low follicular re‐
serve in the donor (aged 32 years), and a delay for the primordial follicles development. In
Patients 2 and 3, the follicular density of the donor ovarian specimen was high and recovery
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of ovarian activity occurred 3.5 months after reimplantation, as observed in the series of
Silber and Gosden [28], who also observed an interval of 3.5 months after reimplantation of
fresh ovarian cortex between monozygotic twins. In addition, the ischemic period was re‐
cently estimated to be between 3 and 5 days by van Eyck et al. [52,53].
7.5. Endocrine function after upper extremity ovarian autotransplantation in girls
Upper-extremity ovarian autologoustransplantation was used in three girls (ages 5, 2, and 1
year) diagnosed with Wilms tumor undergoing abdominal/pelvic radiation therapy at the
tertiary pediatric medical center in the US [54]. Data were availablefor follow-up for 20-25
years.
Patients presented with Wilms tumor underwent surgical resection. Each patient underwent
ovarian autotransplantation to upper extremity in order to move ovarian tissue out of the
radiation field. Subjects 1 and 2 had thin slices from 1 ovary placed in the arm and subject 3
had a free transfer of the entire ovary into the axilla. Subjects 1 and 2 showed spontaneous
follicular development of the autotransplanted ovarian tissue. They had fluctuating gonado‐
tropin and estradiol levels until age 29 and 26, respectively; spontaneous menses until age
29 and 26; and cessation of spontaneous menses with elevated gonadotropins and low estra‐
diol levels at age 30 and 26. Subject 3 had severe monthly axillary pain, and the ovary was
transferred back into the pelvis. She then had ovarian dysfunction with intermittent sponta‐
neous ovarian activity until age 25.
Ovarian autotransplantation to the upper extremity resulted in long-term sex steroid pro‐
duction for spontaneous puberty, menarche, follicular development, and menses with fluc‐
tuating gonadotropin and ovarian sex steroid levels and follicular activity that lasted for
13-15 years.
8. Breast cancer and sex steroid hormone
Breast cancer is the most common cancer in women of reproductive age in the US [55].
Most women with breast cancer require adjuvant chemotherapy including cyclophospha‐
mide. At an average age of 40, administration of cyclophosphamide, methotrexate, and 5-
Fluorouracil  (CMF)  or  Adriamycin,  cyclophosphamide  and  Taxol  (AC+T)  resulted  in
amenorrhea in 20% to 100% or 37% to 77% of patients followed up for 1 year after adju‐
vant chemotherapy, respectively [56].
For fertility preservation, ovarian stimulation with gonadotropins for embryo or oocyte cry‐
opreservation results in excessive levels of estrogen production. To reduce estrogen expo‐
sure during ovarian stimulation in hormone-dependent cancer, a novel protocol using
letrozole (a third generation aromatase inhibitor) and gonadotropins was developed by Dr.
Oktay [57]. (Figure 1) Use of aromatase inhibitors became increasingly common in the treat‐
ment of breast cancer [58]. They have also recently been introduced for ovulation induction.
When compared to clomiphene cycles, they produce comparable peak estradiol levels or
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those even lower than the natural cycle. Because of their dual effects, they can be used in
breast and endometrial cancer patients for ovulation induction. Tamoxifen cannot be used in
those women during ovarian stimulation as it is antagonistic to the endometrium. Based on
our unpublished data, long-term follow-up for up to 7 years, the letrozole protocol showed
safe, efficient, and age-appropriate pregnancy success rates.
Time of Menstrual Cycle (days)
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15
hCG
Letrozole
FSH/hMG
GnRH
antagonist
Letrozole
Figure 1. Protocol for ovarian stimulation with letrozole and gonadotropins in women with breast cancer [57]- NOTE
TO TECH ED: please replace this figure with the one in zipped folder when formatting the chapter (Ana Pantar) and
remove this comment
In North America, Europe, and other parts of the world, aromatase inhibitors are available
for the treatment of postmenopausal breast cancer, but not for ovulation induction. Letro‐
zole and anastrozole are triazole (antifungal) derivatives that are potent, reversible, competi‐
tive, nonsteroidal aromatase inhibitors [59,60]. These drugs inhibit estrogen levels by 97 to
99 percent at doses of 1 to 5 mg/day which result in estrogen concentrations below the level
detected by most sensitive immunoassays. Nonsteroidal aromatase inhibitors are completely
absorbed after oral administration and cleared mainly by the liver. Mean terminal half-life is
approximately 45 hours (range 30 to 60 hours). Exemestane is a steroidal aromatase inhibitor
and its circulating half-life is approximately nine hours, but the inhibitory effect is potential‐
ly much longer because its effect on aromatase is irreversible [61].
Aromatase inhibitors are generally well tolerated and known side effects are hot flushes,
nausea/vomiting, headache, back pain, and leg cramps [60,62,63]. These adverse effects were
reported in older breast cancer patients who were given the drugs on a daily basis over sev‐
eral months in Phase III trials. Very few withdrew from the trials because of drug-related
adverse effects [64,65]. In the clinical experience, using a short course of aromatase inhibitor
for induction of ovulation in young healthy women had fewer side effects than with clomi‐
phene citrate [57,66].
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Ovarian stimulation for embryo or oocyte cryopreservation should be started within the first
four days of the menstrual cycle. Depending on whether the referral is made before or after
breast surgery, usually no more than one or two cycles of ovarian stimulation can be performed
without delaying chemotherapy in women with breast cancer [13]. This delay is generally ac‐
ceptable as multiple studies have shown no effect on survival or recurrence in breast cancer pa‐
tients if chemotherapy had been initiated as late as 12 weeks after breast surgery [67,68].
In fertility preservation cycles, since there is limited time available prior to the onset of che‐
motherapy in breast cancer patients [13], ovarian stimulation is often performed with higher
doses of gonadotropins to maximize the number of embryos or oocytes cryopreserved, and
to increase the likelihood of future pregnancies. In the previous study, we compared a low
dose FSH start (=150 IU) with a high dose (>150 IU) in women with breast cancer undergo‐
ing fertility preservation with letrozole and found that the higher dose FSH stimulation in
letrozole cycles did not improve pregnancy outcomes, and may be associated with a lower
live birth rate [69]. Thus we concluded that higher dose FSH stimulation with letrozole in
women with breast cancer did not improve reproductive outcomes and may be associated
with lower live birth rates. In addition, it may increase estrogen exposure as well as the costs
of fertility preservation.
9. Ovarian suppression using GnRH agonist or antagonist to prevent
gonadal damage
Given the current evidence, both the efficacy and safety of the use of GnRH agonists or an‐
tagonists during chemotherapy for prevention of gonadal damage are controversial. Several
studies have suggested a decreased incidence of amenorrhea with the use of GnRH agonists
throughout chemotherapy; however, most have been non-randomized or small sample
sized studies. Only five randomized trials have been completed.
Badawy et al. [70] and Del Mastro et al. [71] demonstrated the positive effect of GnRH ago‐
nists on the resumption of menses and ovulation; however, Leonard et al. [72], Gerber et al.
[73], and Munster et al. [74] revealed that there was no impact of GnRH agonists on the pre‐
vention of early menopause or ovarian function.
Recently, Partidge [75] reported that women who are interested in future fertility and the
providers who are assisting them should not depend on GnRH agonist treatment during
chemotherapy for preservation of menstrual and ovarian function or fertility. There is one
randomized ongoing study by the Southwest Oncology Group, called the Prevention of Ear‐
ly Menopause Study, a large international multicenter trial. This study will provide addi‐
tional complementary information including biomarkers of ovarian reserve and rates of
long-term amenorrhea or premature ovarian failure in women with or without ovarian sup‐
pression throughout treatment period.
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10. Conclusions
Based on our review, we believe that ovarian cryopreservation and reimplantation in wom‐
en diagnosed with cancer before cancer treatments is an effective option to preserve their
fertility and to restore gonadal endocrine function. Restoration of ovarian activity in terms
of sex steroid production was observed in almost all cases of ovarian reimplantation. All
pregnancies were reported from the orthotopic autotransplantation, but none from the het‐
erotopic autotransplantation. Restoration of endocrine function has been demonstrated con‐
sistently in both methods, although heterotopic sites may not provide an optimal
environment for pregnancy. Physicians should consider the life span and the time period for
the initiation of sex steroid production of transplanted ovarian tissue in order to provide an
exact data, especially when counseling and making a treatment plan for cancer survivors.
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